Optimal Lymph Node Yield for Survival Prediction in Rectal Cancer Patients After Neoadjuvant Therapy

References

• Thorn CC, Woodcock NP, Scott N, Verbeke C, Scott SB, Ambrose NS. What factors affect lymph node yield in surgery for rectal cancer? Colorectal Dis. 2004;6(5):356–361. doi:10.1111/j.1463-1318.2004.00670.x15335370
   PubMedGoogle Scholar
• Mechera R, Schuster T, Rosenberg R, Speich B. Lymph node yield after rectal resection in patients treated with neoadjuvant radiation for rectal cancer: a systematic review and meta-analysis. Eur J Cancer. 2017;72:84–94. doi:10.1016/j.ejca.2016.10.03128027520
   PubMed Web of Science ®Google Scholar
• Abdel-Misih SR, Wei L, Benson AB 3rd, et al. Neoadjuvant therapy for rectal cancer affects lymph node yield and status without clear implications on outcome: the case for eliminating a metric and using preoperative staging to guide therapy. J Natl Compr Canc Netw. 2016;14(12):1528–1534. doi:10.6004/jnccn.2016.016427956537
   PubMed Web of Science ®Google Scholar
• Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114–1123. doi:10.1056/NEJMoa06082916971718
   PubMed Web of Science ®Google Scholar
• Chan DKH, Tan KK. Lower lymph node yield following neoadjuvant therapy for rectal cancer has no clinical significance. J Gastrointest Oncol. 2019;10(1):42–47. doi:10.21037/jgo.2018.10.0230788158
   PubMed Web of Science ®Google Scholar
• Doll D, Gertler R, Maak M, et al. Reduced lymph node yield in rectal carcinoma specimen after neoadjuvant radiochemotherapy has no prognostic relevance. World J Surg. 2009;33(2):340–347. doi:10.1007/s00268-008-9838-819034566
   PubMed Web of Science ®Google Scholar
• Morcos B, Baker B, Al Masri M, Haddad H, Hashem S. Lymph node yield in rectal cancer surgery: effect of preoperative chemoradiotherapy. Eur J Surg Oncol. 2010;36(4):345–349. doi:10.1016/j.ejso.2009.12.00620071133
   PubMed Web of Science ®Google Scholar
• Liang YH, Shao YY, Chen HM, Cheng AL, Lai MS, Yeh KH. Irinotecan and oxaliplatin might provide equal benefit as adjuvant chemotherapy for patients with resectable synchronous colon cancer and liver-confined metastases: a nationwide database study. Anticancer Res. 2017;37(12):7095–7104.29187501
   PubMed Web of Science ®Google Scholar
• Bray F, Parkin DM. Evaluation of data quality in the cancer registry: principles and methods. Part I: comparability, validity and timeliness. Eur J Cancer. 2009;45(5):747–755. doi:10.1016/j.ejca.2008.11.03219117750
   PubMed Web of Science ®Google Scholar
• Chiang CJ, Lo WC, Yang YW, You SL, Chen CJ, Lai MS. Incidence and survival of adult cancer patients in Taiwan, 2002–2012. J Formos Med Assoc. 2016;115(12):1076–1088. doi:10.1016/j.jfma.2015.10.01126786251
   PubMed Web of Science ®Google Scholar
• Chiang NJ, Chen LT, Tsai CR, Chang JS. The epidemiology of gastrointestinal stromal tumors in Taiwan, 1998–2008: a nation-wide cancer registry-based study. BMC Cancer. 2014;14:102. doi:10.1186/1471-2407-14-10224548660
   PubMed Web of Science ®Google Scholar
• Huang Y, Zhang Y, Li J, Liu G. Charlson comorbidity index for evaluation of the outcomes of elderly patients undergoing laparoscopic surgery for colon cancer. J BUON. 2017;22(3):686–691.28730775
   PubMed Web of Science ®Google Scholar
• Tian Y, Xu B, Yu G, Li Y, Liu H. Age-adjusted charlson comorbidity index score as predictor of prolonged postoperative ileus in patients with colorectal cancer who underwent surgical resection. Oncotarget. 2017;8(13):20794–20801. doi:10.18632/oncotarget.1528528206969
   PubMedGoogle Scholar
• DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837–845. doi:10.2307/25315953203132
   PubMed Web of Science ®Google Scholar
• Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst. 2007;99(6):433–441. doi:10.1093/jnci/djk09217374833
   PubMed Web of Science ®Google Scholar
• Benson AB, Venook AP, Al-Hawary MM, et al. NCCN guidelines insights: rectal cancer, version 6.2020. J Natl Compr Canc Netw. 2020;18(7):806–815. doi:10.6004/jnccn.2020.003232634771
   PubMed Web of Science ®Google Scholar
• Cianchi F, Palomba A, Boddi V, et al. Lymph node recovery from colorectal tumor specimens: recommendation for a minimum number of lymph nodes to be examined. World J Surg. 2002;26(3):384–389. doi:10.1007/s00268-001-0236-811865379
   PubMed Web of Science ®Google Scholar
• Ecker BL, McMillan MT, Datta J, et al. Lymph node evaluation and survival after curative-intent resection of duodenal adenocarcinoma: a matched cohort study. Eur J Cancer. 2016;69:135–141. doi:10.1016/j.ejca.2016.09.02727821316
   PubMed Web of Science ®Google Scholar
• Amajoyi R, Lee Y, Recio PJ, Kondylis PD. Neoadjuvant therapy for rectal cancer decreases the number of lymph nodes harvested in operative specimens. Am J Surg. 2013;205(3):289–292; discussion 292. doi:10.1016/j.amjsurg.2012.10.020
   PubMed Web of Science ®Google Scholar
• Govindarajan A, Gonen M, Weiser MR, et al. Challenging the feasibility and clinical significance of current guidelines on lymph node examination in rectal cancer in the era of neoadjuvant therapy. J Clin Oncol. 2011;29(34):4568–4573. doi:10.1200/JCO.2011.37.223521990400
   PubMed Web of Science ®Google Scholar
• Rullier A, Laurent C, Capdepont M, et al. Lymph nodes after preoperative chemoradiotherapy for rectal carcinoma: number, status, and impact on survival. Am J Surg Pathol. 2008;32(1):45–50. doi:10.1097/PAS.0b013e3180dc92ab18162769
   PubMed Web of Science ®Google Scholar
• Kim YW, Kim NK, Min BS, et al. The prognostic impact of the number of lymph nodes retrieved after neoadjuvant chemoradiotherapy with mesorectal excision for rectal cancer. J Surg Oncol. 2009;100(1):1–7. doi:10.1002/jso.2129919418495
   PubMed Web of Science ®Google Scholar
• Lykke J, Jess P, Roikjaer O; Danish Colorectal Cancer G. Increased lymph node yield is associated with improved survival in rectal cancer irrespective of neoadjuvant treatment: results from a national cohort study. Dis Colon Rectum. 2015;58(9):823–830. doi:10.1097/DCR.000000000000042926252843
   PubMed Web of Science ®Google Scholar
• Persiani R, Biondi A, Gambacorta MA, et al. Prognostic implications of the lymph node count after neoadjuvant treatment for rectal cancer. Br J Surg. 2014;101(2):133–142. doi:10.1002/bjs.934124375303
   PubMed Web of Science ®Google Scholar
• Lee CC, Su YC, Hung SK, et al. Recommendation for incorporation of a different lymph node scoring system in future AJCC N category for oral cancer. Sci Rep. 2017;7(1):14117. doi:10.1038/s41598-017-06452-029074847
   PubMed Web of Science ®Google Scholar
• Lee CC, Lin YS, Kang BH, et al. Incorporation of log odds of positive lymph nodes into the AJCC TNM classification improves prediction of survival in oral cancer. Clin Otolaryngol. 2017;42(2):425–432. doi:10.1111/coa.1280927960043
   PubMed Web of Science ®Google Scholar
• Marks JH, Valsdottir EB, Rather AA, Nweze IC, Newman DA, Chernick MR. Fewer than 12 lymph nodes can be expected in a surgical specimen after high-dose chemoradiation therapy for rectal cancer. Dis Colon Rectum. 2010;53(7):1023–1029. doi:10.1007/DCR.0b013e3181dadeb420551754
   PubMed Web of Science ®Google Scholar